Onxeo: Ordinary and Extraordinary General Meeting on April 6, 2016

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE (http://www.businesswire.com/))--
Regulatory News:

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ Copenhagen:
ONXEO), an innovative company specializing in the development of orphan oncology
therapeutics, today announced that Onxeo’s shareholders are invited to attend
the Company’s Combined Ordinary and Extraordinary General Meeting which is being
held on April 6, 2016 at 10.00 AM CET at Onxeo's headquarters: 49 Boulevard du
Général Martial Valin, 75015 Paris, France.

The official notice of the General Meeting was published in the French
Republic's Bulletin des Annonces Légales Obligatoires (i.e. the "Bulletin of
Mandatory Legal Announcements") on March 2, 2016 and includes the agenda, the
draft resolutions, and information on attendance and voting procedures. Under
the conditions set out in current legislation, you can find the notice in its
full length, together with all other related documents, on Onxeo's
website:http://www.onxeo.com/en/investisseurs/assemblee
-generale/ (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.
o 
nxeo.com%2Fen%2Finvestisseurs%2Fassemblee
-generale%2F&esheet=51302064&newsitemid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.onxeo.com%2Fen%2Finvestisseurs%2Fassemblee
-generale%2F&index=1&md5=b5efd5129542aa8bc04f1a53c8da956f).

The above-mentioned documents are available to shareholders at the company's
headquarters and on the Company’s website. Shareholders may request to receive
the documents by sending their request and postal or email address to Onxeo
either by airmail (Direction Financière – 49 boulevard du Général Martial Valin,
75015 Paris, France), fax (+33 1 45 58 08 81), or email (investors@onxeo.com).

About Onxeo

Onxeo is a leading developer of orphan oncology drugs. The Company is focused on
developing innovative therapeutics for rare cancers, one of the fastest growing
markets in the healthcare industry with high, unmet medical needs. Onxeo’s
comprehensive portfolio features a broad orphan oncology pipeline, with three
independent programs in advanced clinical development, including Onxeo’s first
approved orphan oncology drug, Beleodaq®. In addition, Onxeo has successfully
developed and registered two non-cancer products which are currently being
commercialized in the U.S. and Europe. Onxeo’s vision is to become a global
leader and pioneer in oncology, with a focus on orphan or rare cancers, by
developing advanced, effective, and safe therapeutics designed to improve the
lives of patients. The Company is headquartered in Paris, France and has
approximately 50 employees. Onxeo is listed on Euronext in Paris, France
(Ticker: ONXEO, ISIN Code: FR0010095596) and Nasdaq Copenhagen, Denmark (Ticker:
ONXEO).

Onxeo orphan oncology products at the advanced development stage are:

  · Livatag® (Doxorubicin Transdrug™): Currently being evaluated in a Phase III
trial (ReLive) in patients with hepatocellular carcinoma (primary liver cancer);
and in combination with other cancer agents in first-line HCC
  · Beleodaq® (belinostat): FDA-approved in the U.S. in 2014 under the agency’s
accelerated approval program as a second-line treatment for patients with
peripheral T-cell lymphoma (PTCL) and currently marketed by Onxeo’s partner in
the U.S., Spectrum Pharmaceuticals; belinostat in combination with other cancer
agents is currently in development in first-line treatment for patients with
PTCL (BelCHOP) and in other solid tumors
  · Validive® (Clonidine Lauriad®): Positive final results from a Phase II trial
in head and neck cancer patients with severe oral mucositis;

In addition, Onxeo recently reached an agreement to acquire DNA Therapeutics, a
privately-held, clinical-stage biopharmaceutical company, for its first-in
-class, signal-interfering DNA (siDNA) repair technology, which is directed at
overcoming cancer resistance mechanisms. The transaction is expected to close by
the end of March 2016.

Learn more by
visiting www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%
3 
A%2F%2Fwww.onxeo.com&esheet=51302064&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=2&md5=9d6dcc74d75d3a9d98b58d48ef287702).

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Onxeo and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any forward
-looking statements contained herein as a result of new information, future
events or otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the 2014 Reference
Document filed with the AMF on April 14, 2015, which is available on the AMF
website (http://www.amf
-france.org (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww
. 
amf-france.org&esheet=51302064&newsitemid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.amf
-france.org&index=3&md5=bc4b94a4ed60f1306d251b487b770150)) or on the company’s
website
(www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2F
w 
ww.onxeo.com&esheet=51302064&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=4&md5=129db5f05ae09ef6d6fdcb9dbee8bd8d)).
Contacts

Nathalie Delair-Trepo
Investor Relations, Onxeo
investors@onxeo.com
+ 33 1 45 58 76 00
or
Caroline Carmagnol and Florence Portejoie – Alize RP (France)
onxeo@alizerp.com
+33 6 64 18 99 59 / +33 6 47 38 90 04
or
Kirsten Thomas / Lee Roth – The Ruth Group (U.S.)
kthomas@theruthgroup.com / lroth@theruthgroup.com
+1 508 280 6592 / +1 646 536 7012